Village Caregiving reports that frontotemporal dementia is a progressive brain disease affecting behavior, speech, and memory ...

Alector Therapeutics is shelving a GSK-partnered antibody after the asset failed to slow disease progression in patients with ...

Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company focused on developing therapies to counteract the ...

Alector's Phase 3 trial for FTD-GRN drug, latozinemab, failed the clinical co-primary endpoint. The program is discontinued; ...

Treatment did not slow progression of FTD as measured by the clinical co-primary endpointKing of Prussia, Pa., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Biotechnology company Alector announced today that the ...

This open-label Phase 1 study measures safety, peripheral and central inflammation, effects on Treg cell populations, and FTD progression; Five of the 8 planned FTD subjects have been enrolled to date ...

Alector (NASDAQ:ALEC) shares extended post-market losses to drop ~50% in the premarket on Wednesday after the ...

- AVB-101 is an investigational one-time therapy designed to deliver a functional copy of the GRN gene directly to the brain, thereby potentially restoring progranulin levels and stopping disease ...

The immediate consequences of the disappointing result are a big reduction in workforce at South San Francisco-based Alector, ...

Passage Bio reports positive Phase 1/2 trial results for PBFT02 in frontotemporal dementia, with planned protocol amendments for safety optimization. Passage Bio, Inc. announced positive results from ...

Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company focused on developing therapies to counteract the devastating progression ...

Results of study will inform Coya’s randomized, double-blinded Phase 2 trial of COYA 302 in patients with FTD Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage ...